India’s apex drug regulator, the Central Drug Standard Control Organisation (CDSCO), has approved Eli Lilly’s tirzepatide, marketed under the names Mounjaro and Zepbound, for the treatment of type 2 diabetes. Here’s a simple breakdown of the drug and its uses:
What is Tirzepatide?
Tirzepatide is a medication developed by Eli Lilly and Company. It is primarily used to treat type 2 diabetes and has also been effective in promoting weight loss.
How It Works
- Insulin Release: Tirzepatide stimulates the pancreas to release insulin after meals, helping lower blood sugar levels.
- Glucagon Reduction: It reduces the release of glucagon, a hormone that increases blood sugar, thereby helping to lower glucose production by the liver.
- Slows Stomach Emptying: This slows down the emptying of the stomach, reducing the rate at which glucose enters the bloodstream, thus controlling post-meal blood sugar spikes.
- Appetite Reduction: It acts on the brain’s appetite centers to reduce hunger and food intake, which can contribute to weight loss.
Uses in India
Currently, tirzepatide will be marketed in India for the treatment of type 2 diabetes. Its use for weight loss is still under review.
Side Effects
Common side effects include:
- Nausea
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
- Indigestion
- Abdominal pain
Serious side effects may include pancreatitis, low blood sugar when used with other medications, allergic reactions, severe stomach problems, changes in vision, and gallbladder issues.
Precautions
- Usage: Healthcare providers should instruct patients on how to use tirzepatide.
- Low Blood Sugar: Patients should discuss how to manage low blood sugar with their healthcare provider.
- Birth Control: Women using oral contraceptives should consult their healthcare provider, as tirzepatide may affect the effectiveness of birth control pills.
Launch in India
Eli Lilly’s CEO, David Ricks, mentioned that Mounjaro is expected to be launched in India as early as 2025 after completing regulatory reviews.
This approval marks a significant step forward in diabetes management in India, offering patients a new option to help control their condition.
